PRINCETON, N.J., Oct. 27 /PRNewswire/ — Laureate Pharma, Inc.,
a full-service contract development and manufacturing organization,
announced today that they have entered into a development and
manufacturing agreement to produce AV-203, AVEO Pharmaceutical’s
(Cambridge, MA) novel monoclonal antibody targeted against ErbB3.
Laureate’s services will include process development, protein
production, purification and aseptic filling of AP-203 for AVEO.
The project is presently underway and Laureate expects to
supply AVEO with clinical product in the second quarter of 2011.
Terms of the manufacturing agreement were not disclosed.
“AVEO has a very impressive pipeline of monoclonal
antibody-based products for treatment of cancer and we are pleased
to work with them on this exciting antibody product,” said Steve
Johnson, Vice President, Business Development, of Laureate Pharma.
“We look forward to a productive and successful relationship
with AVEO to provide clinical supply of their monoclonal
AV-203 is an ErbB3 (HER3)-targeted antibody. ErbB3 belongs to a
family of four proteins that also includes the epidermal growth
factor receptor (EGFR) and the HER2 receptor. Both EGFR and HER2
have been implicated in promoting the growth of significant numbers
of tumors, particularly in breast and lung cancers. Drugs blocking
the activity of EGFR have demonstrated clinical benefit in lung,
colon and head and neck cancers, while drugs targeting HER2 show
clinical benefit in the treatment of HER2 over-expressing breast
cancers. ErbB3 is significantly over-expressed in many human
breast, ovarian, prostate, colorectal, pancreatic, gastric, and
head and neck cancers, which generally correlates with poor
About Laureate Pharma
Laureate Pharma is a full-service biopharmaceutical contract
development and manufacturing organization. Laureate’s scientists
are expert in process development and cGMP production of